NCT03637400View on ClinicalTrials.gov

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

February 12, 2024

Study Completion Date

June 30, 2025

Conditions
Methicillin-resistant Staphylococcus AureusSkin Infection
Interventions
DRUG

TMP-SMX

TMP-SMX will be administered over a period of 7 days.

DRUG

DOXY

DOXY will be administered over a period of 7 days.

Trial Locations (3)

63130

Washington University, St Louis

90509

Harbor-UCLA Medical Center, Torrance

91342

Olive View-UCLA Medical Center, Sylmar

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Washington University School of Medicine

OTHER

collaborator

University of California, Los Angeles

OTHER

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER